And, from American Association for the Study of Liver Diseases (AASLD):
The new section, “When and in Whom to Initiate HCV Therapy,” offers clinicians information on:
- How to prioritize patients who will derive the most benefit, or will have the greatest impact on limiting further HCV transmission.
- When to treat patients with complications such as advanced fibrosis, compensated cirrhosis, liver transplant, or severe extra-hepatic complications.
- Additional conditions that warrant prioritization of treatment.
Related blog posts: